title: Naloxegol: a review of its use in patients with opioid-induced constipation.
abstract: Oral naloxegol (Movantik™, Moventig(®)), a peripherally acting μ-opioid receptor antagonist, inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract. This article reviews the pharmacological properties of naloxegol and its clinical efficacy and tolerability in patients with opioid-induced constipation. It demonstrated clinical efficacy and was well tolerated in placebo-controlled trials in patients with non-cancer pain and opioid-induced constipation, including those with an inadequate response to laxatives, and was well tolerated in a long-term safety study. As a PEGylated naloxone derivative, naloxegol is associated with significant improvements in spontaneous bowel movements, while maintaining levels of opioid-related analgesia (a result of its reduced ability to cross the blood-brain barrier). Naloxegol is a useful option in the treatment of opioid-induced constipation.
authors: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.
authors: Karly P
authors: KP
authors: Garnock-Jones
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000378:metabolism; D003248:Constipation / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009019:Morphinans / Q000378:metabolism / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000378:metabolism / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors
chemical_list: D000701:Analgesics, Opioid; D009019:Morphinans; D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D011092:Polyethylene Glycols; C000589308:naloxegol